{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:56:43Z","timestamp":1788289003980,"version":"build-2803163510"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the European Union\u2013 Next Generation EU","award":["LX22NPO5104"],"award-info":[{"award-number":["LX22NPO5104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Diabetic foot infections (DFIs) contribute to the global disability burden. Beta-lactams are the most commonly used antibiotics for treating DFIs. However, the use of antibiotics may lead to disruption of the healthy balance of the gut microbiota, causing dysbiosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with infected diabetic foot ulcers (iDFUs) were treated with two kinds of beta-lactams (amoxicillin\/clavulanic acid or ceftazidime) according to microbial sensitivity of causative agents via bolus or continuous administration modes. Changes in the gut microbiome of patients were analyzed. Diabetic patients without iDFUs were used as a control group. 16\u00a0S ribosomal RNA gene amplicon sequencing was performed on stool samples collected from participants.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Alpha diversity and beta diversity of gut microbiota of treated patients did not show significant differences between bolus and continuous modes. However, significant differences were observed between gut microbiota diversity of treated patients and control group. PCoA plots showed individualized responses of the patient\u2019s gut microbiota to antibiotics at different times using both administration forms associated with the pre-treatment state of microbiota composition. <jats:italic>Enterococcus<\/jats:italic>, <jats:italic>Sellimonas<\/jats:italic>, and <jats:italic>Lachnoclostridium<\/jats:italic> were the common bacterial markers differentially abundant in the gut microbiota of antibiotic-treated patients with iDFUs while <jats:italic>Roseburia<\/jats:italic>, <jats:italic>Dorea<\/jats:italic>, and <jats:italic>Monoglobus<\/jats:italic> were mainly abundant in the gut microbiota of patients without iDFUs. Predicted pathways like \u201cTransporters\u201d, \u201cABC transporters\u201d and \u201cPhosphotranspherase system (PTS)\u201d were upregulated in the gut microbiome of patients treated with bolus regime which may lead to increased intestinal barrier permeability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The present study reported alterations in gut microbiota composition and functionality and provided the bacterial markers as well as potential metabolic signatures associated with each administration mode in patients with iDFUs, which may be used as a reference set for future studies of the effect of antibiotics administration on the gut microbiome of patients with iDFUs. This study shed light on the importance of understanding the effect of antibiotic administration form on gut microbiome in patients with iDFUs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>The DFIATIM Clinical Trial (Full title: \u201cRationalisation of ATB therapy in diabetic foot infection and its impact on the intestinal microbiota\u201d) is submitted to the European Union Clinical Trials Database under the EudraCT Number: 2019-001997-27. The date of registration is July 17th, 2020.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12866-025-04041-0","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T05:02:45Z","timestamp":1748408565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effect of the administration form of antibiotic therapy on the gut microbiome in patients with infected diabetic foot ulcers - DFIATIM trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Chahrazed","family":"Mekadim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Mrazek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina Ol\u0161a","family":"Fliegerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Sechovcov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana Maria","family":"Mahayri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Jaro\u0161\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"Hus\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Woskov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"T\u016fma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Pol\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Soj\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"N\u011bmcov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Dubsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edra","family":"Fejfarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"4041_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2337\/dci22-0043","volume":"46","author":"K McDermott","year":"2023","unstructured":"McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers. Diabetes Care. 2023;46:209\u201311. https:\/\/doi.org\/10.2337\/dci22-0043.","journal-title":"Diabetes Care"},{"key":"4041_CR2","doi-asserted-by":"publisher","unstructured":"Del Core MA, Ahn J, Lewis RB, Raspovic KM, Lalli TAJ, Wukich DK. The evaluation and treatment of diabetic foot ulcers and diabetic foot infections. Foot Ankle Orthop. 2018;3. https:\/\/doi.org\/10.1177\/2473011418788864.","DOI":"10.1177\/2473011418788864"},{"key":"4041_CR3","doi-asserted-by":"publisher","unstructured":"Anwander H, Vonwyl D, Hecht V, Tannast M, Kurze C, Krause F. Risk factors for failure after surgery in patients with diabetic foot syndrome. Foot Ankle Orthop. 2023;8. https:\/\/doi.org\/10.1177\/24730114231182656.","DOI":"10.1177\/24730114231182656"},{"key":"4041_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.22467\/jwmr.2023.02747","volume":"19","author":"JH Kim","year":"2023","unstructured":"Kim JH. Investigating diabetic foot pathophysiology and amputation prevention strategies through behavioral modification. J Wound Manag Res. 2023;19:167\u201372. https:\/\/doi.org\/10.22467\/jwmr.2023.02747.","journal-title":"J Wound Manag Res"},{"key":"4041_CR5","first-page":"386","volume":"104","author":"EM Matheson","year":"2021","unstructured":"Matheson EM, Bragg SW, Blackwelder RS. Diabetes-related foot infections: diagnosis and treatment. Am Fam Physician. 2021;104:386\u201394.","journal-title":"Am Fam Physician"},{"key":"4041_CR6","doi-asserted-by":"publisher","unstructured":"Senneville \u00c9, Albalawi Z, van Asten SA, Abbas ZG, Allison G, Arag\u00f3n-S\u00e1nchez J, et al. IWGDF\/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF\/IDSA 2023). Clin Infect Dis. 2023;1\u201323. https:\/\/doi.org\/10.1093\/cid\/ciad527.","DOI":"10.1093\/cid\/ciad527"},{"key":"4041_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.avsg.2015.11.025","volume":"33","author":"CW Hicks","year":"2016","unstructured":"Hicks CW, Selvarajah S, Mathioudakis N, Sherman RE, Hines KF, et al. Burden of infected diabetic foot ulcers on hospital admissions and costs. Ann Vasc Surg. 2016;33:149\u201358. https:\/\/doi.org\/10.1016\/j.avsg.2015.11.025.","journal-title":"Ann Vasc Surg"},{"key":"4041_CR8","first-page":"123","volume":"27","author":"Pavl\u00edna Vladim\u00edra Fejfarov\u00e1","year":"2024","unstructured":"Vladim\u00edra Fejfarov\u00e1 Pavl\u00edna, Pi\u0165hov\u00e1 A, Jirkovsk\u00e1 M, Koliba J, Jirkovsk\u00e1. Hana K\u016fsov\u00e1 BS. \u010cinnost podiatrie ve sv\u011btle Posledn\u00edch let (The activities of Czech podiatry in the light of recent years). Diabetologie. 2024;27:123\u20138.","journal-title":"Diabetologie"},{"key":"4041_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/cid\/cis346","volume":"54","author":"BA Lipsky","year":"2012","unstructured":"Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJG, Armstrong DG, et al. Infectious diseases society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54:132\u201373. https:\/\/doi.org\/10.1093\/cid\/cis346.","journal-title":"Clin Infect Dis"},{"key":"4041_CR10","unstructured":"Bader MS. Diabetic foot infection. Am Fam Physician. 2008;78."},{"key":"4041_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1469-0691.2007.01697.x","volume":"13","author":"BA Lipsky","year":"2007","unstructured":"Lipsky BA. Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection? Clin Microbiol Infect. 2007;13:351\u20133. https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01697.x.","journal-title":"Clin Microbiol Infect"},{"issue":"3\u20134","key":"4041_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1574-695X.1999.tb01398.x","volume":"26","author":"BA Lipsky","year":"1999","unstructured":"Lipsky BA. Antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol. 1999;26(3\u20134):267\u201376. https:\/\/doi.org\/10.1111\/j.1574-695X.1999.tb01398.x.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"4041_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2110-5820-2-37","volume":"2","author":"MH Abdul-Aziz","year":"2012","unstructured":"Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care. 2012;2:1. https:\/\/doi.org\/10.1186\/2110-5820-2-37.","journal-title":"Ann Intensive Care"},{"key":"4041_CR14","first-page":"94","volume":"78","author":"MH Abdul-Aziz","year":"2012","unstructured":"Abdul-Aziz MH, Staatz CE, Kirkpatrick CM, Lipman J, Roberts JA. Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics. Minerva Anestesiol. 2012;78:94\u2013104.","journal-title":"Minerva Anestesiol"},{"key":"4041_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","volume":"43","author":"LT Hong","year":"2023","unstructured":"Hong LT, Downes KJ, FakhriRavari A, Abdul-Mutakabbir JC, Kuti JL, Jorgensen S, et al. International consensus recommendations for the use of prolonged\u2010infusion beta\u2010lactam antibiotics: endorsed by the American college of clinical pharmacy, British society for antimicrobial chemotherapy, cystic fibrosis foundation, European society of clini. Pharmacother J Hum Pharmacol Drug Ther. 2023;43:740\u201377. https:\/\/doi.org\/10.1002\/phar.2842.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"4041_CR16","doi-asserted-by":"publisher","first-page":"102293","DOI":"10.1016\/j.eclinm.2023.102293","volume":"65","author":"KA Budai","year":"2023","unstructured":"Budai KA, T\u00edm\u00e1r \u00c1E, Obeidat M, M\u00e1t\u00e9 V, Nagy R, Harnos A, et al. Extended infusion of \u03b2-lactams significantly reduces mortality and enhances Microbiological eradication in paediatric patients: a systematic review and meta-analysis. eClinicalMedicine. 2023;65:102293. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102293.","journal-title":"eClinicalMedicine"},{"key":"4041_CR17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41579-023-00933-y","volume":"21","author":"SRS Fishbein","year":"2023","unstructured":"Fishbein SRS, Mahmud B, Dantas G. Antibiotic perturbations to the gut Microbiome. Nat Rev Microbiol. 2023;21:772\u201388. https:\/\/doi.org\/10.1038\/s41579-023-00933-y.","journal-title":"Nat Rev Microbiol"},{"key":"4041_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-022-00685-9","volume":"20","author":"AC Fenneman","year":"2023","unstructured":"Fenneman AC, Weidner M, Chen LA, Nieuwdorp M, Blaser MJ. Antibiotics in the pathogenesis of diabetes and inflammatory diseases of the Gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2023;20:81\u2013100. https:\/\/doi.org\/10.1038\/s41575-022-00685-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4041_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/dom.12637","volume":"18","author":"KH Mikkelsen","year":"2016","unstructured":"Mikkelsen KH, Allin KH, Knop FK. Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: A review of the literature. Diabetes Obes Metab. 2016;18:444\u201353. https:\/\/doi.org\/10.1111\/dom.12637.","journal-title":"Diabetes Obes Metab"},{"key":"4041_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2017.02306","volume":"8 NOV","author":"RR Rodrigues","year":"2017","unstructured":"Rodrigues RR, Greer RL, Dong X, DSouza KN, Gurung M, Wu JY, et al. Antibiotic-induced alterations in gut microbiota are associated with changes in glucose metabolism in healthy mice. Front Microbiol. 2017;8 NOV:1\u201314. https:\/\/doi.org\/10.3389\/fmicb.2017.02306.","journal-title":"Front Microbiol"},{"key":"4041_CR21","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/ije\/dyaa122","volume":"49","author":"J Yuan","year":"2020","unstructured":"Yuan J, Hu YJ, Zheng J, Kim JH, Sumerlin T, Chen Y, et al. Long-term use of antibiotics and risk of type 2 diabetes in women: A prospective cohort study. Int J Epidemiol. 2020;49:1572\u201381. https:\/\/doi.org\/10.1093\/ije\/dyaa122.","journal-title":"Int J Epidemiol"},{"key":"4041_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.202104965","volume":"9","author":"M Shuai","year":"2022","unstructured":"Shuai M, Zhang G, Zeng F, fang, Fu Y, Liang X, Yuan L, et al. Human gut antibiotic resistome and progression of diabetes. Adv Sci. 2022;9:1\u201314. https:\/\/doi.org\/10.1002\/advs.202104965.","journal-title":"Adv Sci"},{"key":"4041_CR23","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1124\/dmd.122.000906","volume":"50","author":"X Chen","year":"2022","unstructured":"Chen X, Liu Y, Yao H, Song W, Song Y, Gu J, et al. Antibiotics-induced disruption of gut microbiota increases systemic exposure of clopidogrel active metabolite in type 2 diabetic rats. Drug Metab Dispos. 2022;50:1142\u201350. https:\/\/doi.org\/10.1124\/dmd.122.000906.","journal-title":"Drug Metab Dispos"},{"key":"4041_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/JOE-17-0709","volume":"238","author":"L Fu","year":"2018","unstructured":"Fu L, Qiu Y, Shen L, Cui C, Wang S, Wang S, et al. The delayed effects of antibiotics in type 2 diabetes, friend or foe? J Endocrinol. 2018;238:137\u201349. https:\/\/doi.org\/10.1530\/JOE-17-0709.","journal-title":"J Endocrinol"},{"key":"4041_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ismej.2015.114","volume":"10","author":"K Brown","year":"2016","unstructured":"Brown K, Godovannyi A, Ma C, Zhang Y, Ahmadi-Vand Z, Dai C, et al. Prolonged antibiotic treatment induces a diabetogenic intestinal Microbiome that accelerates diabetes in NOD mice. ISME J. 2016;10:321\u201332. https:\/\/doi.org\/10.1038\/ismej.2015.114.","journal-title":"ISME J"},{"key":"4041_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12223-023-01119-y","volume":"69","author":"H Sechovcov\u00e1","year":"2024","unstructured":"Sechovcov\u00e1 H, Mahayri TM, Mr\u00e1zek J, Jaro\u0161\u00edkov\u00e1 R, Hus\u00e1kov\u00e1 J, Woskov\u00e1 V, et al. Gut microbiota in relationship to diabetes mellitus and its late complications with a focus on diabetic foot syndrome: A review. Folia Microbiol (Praha). 2024;69:259\u201382. https:\/\/doi.org\/10.1007\/s12223-023-01119-y.","journal-title":"Folia Microbiol (Praha)"},{"key":"4041_CR27","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.ebiom.2019.11.051","volume":"51","author":"M Gurung","year":"2020","unstructured":"Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590. https:\/\/doi.org\/10.1016\/j.ebiom.2019.11.051.","journal-title":"EBioMedicine"},{"key":"4041_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2022.1029890","volume":"13","author":"J Ye","year":"2022","unstructured":"Ye J, Wu Z, Zhao Y, Zhang S, Liu W, Su Y. Role of gut microbiota in the pathogenesis and treatment of diabetes mullites: advanced research-based review. Front Microbiol. 2022;13:1\u201313.","journal-title":"Front Microbiol"},{"key":"4041_CR29","doi-asserted-by":"publisher","unstructured":"Larsen N, Vogensen FK, Van Den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE. 2010;5. https:\/\/doi.org\/10.3389\/fmicb.2022.1029890.","DOI":"10.3389\/fmicb.2022.1029890"},{"key":"4041_CR30","doi-asserted-by":"publisher","first-page":"108645","DOI":"10.1016\/j.diabres.2020.108645","volume":"172","author":"S Zhang","year":"2021","unstructured":"Zhang S, Cai Y, Meng C, Ding X, Huang J, Luo X, et al. The role of the Microbiome in diabetes mellitus. Diabetes Res Clin Pract. 2021;172:108645. https:\/\/doi.org\/10.1016\/j.diabres.2020.108645.","journal-title":"Diabetes Res Clin Pract"},{"key":"4041_CR31","first-page":"1","volume":"12","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Sun B, Yu D, Zhu C. Gut microbiota: an important player in type 2 diabetes mellitus. Front Cell Infect Microbiol. 2022;12:1\u201315.","journal-title":"Front Cell Infect Microbiol"},{"key":"4041_CR32","doi-asserted-by":"publisher","unstructured":"Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE. 2013;8. https:\/\/doi.org\/10.1371\/journal.pone.0071108.","DOI":"10.1371\/journal.pone.0071108"},{"key":"4041_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2891-13-60","volume":"13","author":"AC Gomes","year":"2014","unstructured":"Gomes AC, Bueno AA, Mota RGM, de S. Gut microbiota, probiotics and diabetes. Nutr J. 2014;13:1\u201313. https:\/\/doi.org\/10.1186\/1475-2891-13-60.","journal-title":"Nutr J"},{"key":"4041_CR34","doi-asserted-by":"publisher","first-page":"632335","DOI":"10.3389\/fendo.2021.632335","volume":"12","author":"MN Huda","year":"2021","unstructured":"Huda MN, Kim M, Bennett BJ. Modulating the microbiota as a therapeutic intervention for type 2 diabetes. Front Endocrinol. 2021;12:632335. https:\/\/doi.org\/10.3389\/fendo.2021.632335.","journal-title":"Front Endocrinol"},{"key":"4041_CR35","doi-asserted-by":"publisher","first-page":"113148","DOI":"10.1016\/j.biopha.2022.113148","volume":"152","author":"BR Sharma","year":"2022","unstructured":"Sharma BR, Jaiswal S, Ravindra PV. Modulation of gut microbiota by bioactive compounds for prevention and management of type 2 diabetes. Biomed Pharmacother. 2022;152:113148. https:\/\/doi.org\/10.1016\/j.biopha.2022.113148.","journal-title":"Biomed Pharmacother"},{"key":"4041_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/foods11162438","volume":"11","author":"H Jiang","year":"2022","unstructured":"Jiang H, Cai M, Shen B, Wang Q, Zhang T, Zhou X. Synbiotics and gut microbiota: new perspectives in the treatment of type 2 diabetes mellitus. Foods. 2022;11:1\u201318. https:\/\/doi.org\/10.3390\/foods11162438.","journal-title":"Foods"},{"key":"4041_CR37","doi-asserted-by":"publisher","unstructured":"Vitetta L, Gorgani NN, Vitetta G, Henson JD. Prebiotics progress shifts in the intestinal Microbiome that benefits patients with type 2 diabetes mellitus. Biomolecules. 2023;13. https:\/\/doi.org\/10.3390\/biom13091307.","DOI":"10.3390\/biom13091307"},{"key":"4041_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.930872","volume":"13 August","author":"L He","year":"2022","unstructured":"He L, Chen R, Zhang B, Zhang S, Khan BA, Zhu D, et al. Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes mellitus. Front Immunol. 2022;13 August:1\u201317. https:\/\/doi.org\/10.3389\/fimmu.2022.930872.","journal-title":"Front Immunol"},{"key":"4041_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2022.820367","volume":"12 March","author":"D Ding","year":"2022","unstructured":"Ding D, Yong H, You N, Lu W, Yang X, Ye X, et al. Prospective study reveals host microbial determinants of clinical response to fecal microbiota transplant therapy in type 2 diabetes patients. Front Cell Infect Microbiol. 2022;12 March:1\u201312. https:\/\/doi.org\/10.3389\/fcimb.2022.820367.","journal-title":"Front Cell Infect Microbiol"},{"key":"4041_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jaut.2014.03.005","volume":"53 C","author":"J Peng","year":"2014","unstructured":"Peng J, Narasimhan S, Marchesi JR, Benson A, Wong FS, Wen L. Long term effect of gut microbiota transfer on diabetes development. J Autoimmun. 2014;53\u00a0C:85\u201394. https:\/\/doi.org\/10.1016\/j.jaut.2014.03.005.","journal-title":"J Autoimmun"},{"key":"4041_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2022.1089991","volume":"12","author":"Z Wu","year":"2023","unstructured":"Wu Z, Zhang B, Chen F, Xia R, Zhu D, Chen B, et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study. Front Cell Infect Microbiol. 2023;12:1\u201314. https:\/\/doi.org\/10.3389\/fcimb.2022.1089991.","journal-title":"Front Cell Infect Microbiol"},{"key":"4041_CR42","doi-asserted-by":"publisher","unstructured":"Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes. Nutrients. 2022;14. https:\/\/doi.org\/10.3390\/nu14010166.","DOI":"10.3390\/nu14010166"},{"key":"4041_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics14112543","volume":"14","author":"A Awasthi","year":"2022","unstructured":"Awasthi A, Corrie L, Vishwas S, Gulati M, Kumar B, Chellappan DK, et al. Gut dysbiosis and diabetic foot ulcer: role of probiotics. Pharmaceutics. 2022;14:1\u201326. https:\/\/doi.org\/10.3390\/pharmaceutics14112543.","journal-title":"Pharmaceutics"},{"key":"4041_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms9020353","volume":"9","author":"B Pessemier","year":"2021","unstructured":"Pessemier B, De, Grine L, Debaere M, Maes A, Paetzold B, Callewaert C. Gut\u2013skin axis: current knowledge of the interrelationship between microbial dysbiosis and skin conditions. Microorganisms. 2021;9:1\u201333. https:\/\/doi.org\/10.3390\/microorganisms9020353.","journal-title":"Microorganisms"},{"key":"4041_CR45","doi-asserted-by":"publisher","unstructured":"Mohseni S, Bayani M, Bahmani F, Tajabadi-Ebrahimi M, Bayani MA, Jafari P, et al. The beneficial effects of probiotic administration on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial. Diabetes Metab Res Rev. 2018;34. https:\/\/doi.org\/10.1002\/dmrr.2970.","DOI":"10.1002\/dmrr.2970"},{"key":"4041_CR46","doi-asserted-by":"publisher","unstructured":"Patel BK, Patel KH, Huang RY, Lee CN, Moochhala SM. The gut-skin microbiota axis and its role in diabetic wound healing\u2014a review based on current literature. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23042375.","DOI":"10.3390\/ijms23042375"},{"key":"4041_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2024.1326179","volume":"15 May","author":"V Fejfarov\u00e1","year":"2024","unstructured":"Fejfarov\u00e1 V, Jaro\u0161\u00edkov\u00e1 R, Antalov\u00e1 S, Hus\u00e1kov\u00e1 J, Woskov\u00e1 V, Beca P, et al. Does PAD and microcirculation status impact the tissue availability of intravenously administered antibiotics in patients with infected diabetic foot? Results of the DFIATIM substudy. Front Endocrinol (Lausanne). 2024;15 May:1\u201311. https:\/\/doi.org\/10.3389\/fendo.2024.1326179.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4041_CR48","doi-asserted-by":"publisher","unstructured":"Milani C, Hevia A, Foroni E, Duranti S, Turroni F, Lugli GA, et al. Assessing the fecal microbiota: an optimized ion torrent 16s Rrna gene-based analysis protocol. PLoS ONE. 2013;8. https:\/\/doi.org\/10.1371\/journal.pone.0068739.","DOI":"10.1371\/journal.pone.0068739"},{"key":"4041_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-022-02458-5","volume":"22","author":"C Mekadim","year":"2022","unstructured":"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V, et al. Dysbiosis of skin Microbiome and gut Microbiome in melanoma progression. BMC Microbiol. 2022;22:1\u201319. https:\/\/doi.org\/10.1186\/s12866-022-02458-5.","journal-title":"BMC Microbiol"},{"key":"4041_CR50","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","volume":"37","author":"E Bolyen","year":"2019","unstructured":"Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive, scalable and extensible Microbiome data science using QIIME 2. Nat Biotechnol. 2019;37:852\u20137. https:\/\/doi.org\/10.1038\/s41587-019-0209-9.","journal-title":"Nat Biotechnol"},{"key":"4041_CR51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution sample inference from illumina amplicon data. Nat Methods. 2016;13:581\u20133. https:\/\/doi.org\/10.1038\/nmeth.3869.","journal-title":"Nat Methods"},{"key":"4041_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7717\/peerj.2584","volume":"2016","author":"T Rognes","year":"2016","unstructured":"Rognes T, Flouri T, Nichols B, Quince C, Mah\u00e9 F. VSEARCH: A versatile open source tool for metagenomics. PeerJ. 2016;2016:1\u201322. https:\/\/doi.org\/10.7717\/peerj.2584.","journal-title":"PeerJ"},{"key":"4041_CR53","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41587-020-0548-6","volume":"38","author":"GM Douglas","year":"2020","unstructured":"Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, et al. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol. 2020;38:685\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0548-6.","journal-title":"Nat Biotechnol"},{"key":"4041_CR54","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1038\/s41587-020-0548-6","volume":"30","author":"DH Parks","year":"2014","unstructured":"Parks DH, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics. 2014;30:3123\u20134. https:\/\/doi.org\/10.1038\/s41587-020-0548-6.","journal-title":"Bioinformatics"},{"key":"4041_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2021.586875","volume":"8 March","author":"B Levast","year":"2021","unstructured":"Levast B, Benech N, Gasc C, Batailler C, Senneville E, Lustig S, et al. Impact on the gut microbiota of intensive and prolonged antimicrobial therapy in patients with bone and joint infection. Front Med. 2021;8 March:1\u201314. https:\/\/doi.org\/10.3389\/fmed.2021.586875.","journal-title":"Front Med"},{"key":"4041_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2020.572912","volume":"10 November","author":"J Ramirez","year":"2020","unstructured":"Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 2020;10 November:1\u201310. https:\/\/doi.org\/10.3389\/fcimb.2020.572912.","journal-title":"Front Cell Infect Microbiol"},{"key":"4041_CR57","doi-asserted-by":"publisher","unstructured":"Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, et al. Antibiotic-induced shifts in the mouse gut Microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5. https:\/\/doi.org\/10.1038\/ncomms4114.","DOI":"10.1038\/ncomms4114"},{"key":"4041_CR58","doi-asserted-by":"publisher","unstructured":"Langdon A, Crook N, Dantas G. The effects of antibiotics on the Microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8. https:\/\/doi.org\/10.1186\/s13073-016-0294-z.","DOI":"10.1186\/s13073-016-0294-z"},{"key":"4041_CR59","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.molmed.2016.04.003","volume":"22","author":"S Becattini","year":"2016","unstructured":"Becattini S, Taur Y, Pamer EG. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol Med. 2016;22:458\u201378. https:\/\/doi.org\/10.1016\/j.molmed.2016.04.003.","journal-title":"Trends Mol Med"},{"key":"4041_CR60","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1172\/JCI72333","volume":"124","author":"SR Modi","year":"2014","unstructured":"Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest. 2014;124:4212\u20138. https:\/\/doi.org\/10.1172\/JCI72333.","journal-title":"J Clin Invest"},{"key":"4041_CR61","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/gutjnl-2016-312297","volume":"65","author":"G Ianiro","year":"2016","unstructured":"Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65:1906\u201315. https:\/\/doi.org\/10.1136\/gutjnl-2016-312297.","journal-title":"Gut"},{"key":"4041_CR62","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jnutbio.2018.10.003","volume":"63","author":"S Sharma","year":"2019","unstructured":"Sharma S, Tripathi P. Gut Microbiome and type 2 diabetes: where we are and where to go? J Nutr Biochem. 2019;63:101\u20138. https:\/\/doi.org\/10.1016\/j.jnutbio.2018.10.003.","journal-title":"J Nutr Biochem"},{"key":"4041_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-016-2777-0","volume":"17","author":"M Pop","year":"2016","unstructured":"Pop M, Paulson JN, Chakraborty S, Astrovskaya I, Lindsay BR, Li S, et al. Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent Ciprofloxacin treatment. BMC Genomics. 2016;17:1\u201311. https:\/\/doi.org\/10.1186\/s12864-016-2777-0.","journal-title":"BMC Genomics"},{"key":"4041_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40168-021-01170-2","volume":"9","author":"A Rashidi","year":"2021","unstructured":"Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Nalluri H, Kaiser T, et al. Gut microbiota response to antibiotics is personalized and depends on baseline microbiota. Microbiome. 2021;9:1\u201311. https:\/\/doi.org\/10.1186\/s40168-021-01170-2.","journal-title":"Microbiome"},{"key":"4041_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/0102-672020190001e1498","volume":"33","author":"LF Campos","year":"2020","unstructured":"Campos LF, Tagliari E, Casagrande TAC, de Noronha L, Campos ACL, Matias JEF. Effects of probiotics supplementation on skin wound healing in diabetic rats. Arq Bras Cir Dig. 2020;33:1\u20136. https:\/\/doi.org\/10.1590\/0102-672020190001e1498.","journal-title":"Arq Bras Cir Dig"},{"key":"4041_CR66","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/bab.2064","volume":"68","author":"M Mohtashami","year":"2021","unstructured":"Mohtashami M, Mohamadi M, Azimi-Nezhad M, Saeidi J, Nia FF, Ghasemi A. Lactobacillus bulgaricus and Lactobacillus plantarum improve diabetic wound healing through modulating inflammatory factors. Biotechnol Appl Biochem. 2021;68:1421\u201331. https:\/\/doi.org\/10.1002\/bab.2064.","journal-title":"Biotechnol Appl Biochem"},{"key":"4041_CR67","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.4345","volume":"23","author":"H Wu","year":"2017","unstructured":"Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manner\u00e5s-Holm L, et al. Metformin alters the gut Microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23:850\u20138. https:\/\/doi.org\/10.1038\/nm.4345.","journal-title":"Nat Med"},{"key":"4041_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2017.00214","volume":"8 FEB","author":"SS Bhute","year":"2017","unstructured":"Bhute SS, Suryavanshi MV, Joshi SM, Yajnik CS, Shouche YS, Ghaskadbi SS. Gut microbial diversity assessment of Indian type-2-diabetics reveals alterations in eubacteria, archaea, and eukaryotes. Front Microbiol. 2017;8 FEB:1\u201315. https:\/\/doi.org\/10.3389\/fmicb.2017.00214.","journal-title":"Front Microbiol"},{"key":"4041_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-021-00856-4","volume":"13","author":"C Alvarez-Silva","year":"2021","unstructured":"Alvarez-Silva C, Kashani A, Hansen TH, Pinna NK, Anjana RM, Dutta A, et al. Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India. Genome Med. 2021;13:1\u201313. https:\/\/doi.org\/10.1186\/s13073-021-00856-4.","journal-title":"Genome Med"},{"key":"4041_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature12198","volume":"498","author":"FH Karlsson","year":"2013","unstructured":"Karlsson FH, Tremaroli V, Nookaew I, Bergstr\u00f6m G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99\u2013103. https:\/\/doi.org\/10.1038\/nature12198.","journal-title":"Nature"},{"key":"4041_CR71","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.micpath.2017.08.038","volume":"111","author":"M Sedighi","year":"2017","unstructured":"Sedighi M, Razavi S, Navab-Moghadam F, Khamseh ME, Alaei-Shahmiri F, Mehrtash A, et al. Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. Microb Pathog. 2017;111:362\u20139. https:\/\/doi.org\/10.1016\/j.micpath.2017.08.038.","journal-title":"Microb Pathog"},{"key":"4041_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-024-01424-7","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu J, Chen Y, Peng C. The causal relationship between gut microbiota and diabetic neuropathy: a bi-directional two-sample Mendelian randomization study. Diabetol Metab Syndr. 2024;15:1\u201312. https:\/\/doi.org\/10.1186\/s13098-024-01424-7.","journal-title":"Diabetol Metab Syndr"},{"key":"4041_CR73","doi-asserted-by":"publisher","unstructured":"Zhao X, Zhang Y, Guo R, Yu W, Zhang F, Wu F et al. The alteration in composition and function of gut microbiome in patients with type 2 diabetes. J Diabetes Res. 2020;2020; https:\/\/doi.org\/10.1155\/2020\/8842651","DOI":"10.1155\/2020\/8842651"},{"key":"4041_CR74","doi-asserted-by":"publisher","first-page":"E113","DOI":"10.1152\/AJPENDO.00471.2020","volume":"320","author":"B Wei","year":"2021","unstructured":"Wei B, Wang Y, Xiang S, Jiang Y, Chen R, Hu N. Alterations of gut Microbiome in patients with type 2 diabetes mellitus who had undergone cholecystectomy. Am J Physiol - Endocrinol Metab. 2021;320:E113\u201321. https:\/\/doi.org\/10.1152\/AJPENDO.00471.2020.","journal-title":"Am J Physiol - Endocrinol Metab"},{"key":"4041_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-49679-w","volume":"13","author":"NR Dash","year":"2023","unstructured":"Dash NR, Al Bataineh MT, Alili R, Al Safar H, Alkhayyal N, Prifti E, et al. Functional alterations and predictive capacity of gut Microbiome in type 2 diabetes. Sci Rep. 2023;13:1\u201312. https:\/\/doi.org\/10.1038\/s41598-023-49679-w.","journal-title":"Sci Rep"},{"key":"4041_CR76","doi-asserted-by":"publisher","first-page":"109873","DOI":"10.1016\/j.biopha.2020.109873","volume":"124","author":"Q Ma","year":"2020","unstructured":"Ma Q, Li Y, Wang J, Li P, Duan Y, Dai H, et al. Investigation of gut Microbiome changes in type 1 diabetic mellitus rats based on high-throughput sequencing. Biomed Pharmacother. 2020;124:109873. https:\/\/doi.org\/10.1016\/j.biopha.2020.109873.","journal-title":"Biomed Pharmacother"},{"key":"4041_CR77","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/iwj.13766","volume":"19","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang H, Ma G, Tian Z, Wang B. The contribution of intestinal Streptococcus to the pathogenesis of diabetic foot ulcers: an analysis based on 16S rRNA sequencing. Int Wound J. 2022;19:1658\u201368. https:\/\/doi.org\/10.1111\/iwj.13766.","journal-title":"Int Wound J"},{"key":"4041_CR78","doi-asserted-by":"publisher","unstructured":"Kaur P, Choudhury D. Modulation of inflammatory dynamics by insulin to promote wound recovery of diabetic ulcers. Wound Heal. 2020;1\u201321. https:\/\/doi.org\/10.5772\/intechopen.92096.","DOI":"10.5772\/intechopen.92096"},{"issue":"12","key":"4041_CR79","doi-asserted-by":"publisher","first-page":"e1009186","DOI":"10.1371\/journal.pgen.1009186","volume":"16","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Verboon JM, Allen TE, Abreu-Blanco MT, Liu R, Dominguez ANM, et al. Autocrine insulin pathway signaling regulates actin dynamics in cell wound repair. PLoS Genet. 2020;16(12):e1009186. https:\/\/doi.org\/10.1371\/journal.pgen.1009186.","journal-title":"PLoS Genet"},{"key":"4041_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0036974","volume":"7","author":"MHM Lima","year":"2012","unstructured":"Lima MHM, Caricilli AM, de Abreu LL, Ara\u00fajo EP, Pelegrinelli FF, Thirone ACP, et al. Topical insulin accelerates wound healing in diabetes by enhancing the AKT and ERK pathways: A double-blind placebo-controlled clinical trial. PLoS ONE. 2012;7:1\u201313. https:\/\/doi.org\/10.1371\/journal.pone.0036974.","journal-title":"PLoS ONE"},{"key":"4041_CR81","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15406\/japlr.2016.02.00007","volume":"2","author":"DH AbdelKader","year":"2016","unstructured":"AbdelKader DH, Osman MA, Elgizawy SA, Faheem AM, McCarron PA. The role of insulin in wound healing process: mechanism of action and pharmaceutical applications. J Anal Pharm Res. 2016;2:7\u201310. https:\/\/doi.org\/10.15406\/japlr.2016.02.00007.","journal-title":"J Anal Pharm Res"},{"key":"4041_CR82","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3164\/jcbn.17-44","volume":"61","author":"R Inoue","year":"2017","unstructured":"Inoue R, Ohue-Kitano R, Tsukahara T, Tanaka M, Masuda S, Inoue T, et al. Prediction of functional profiles of gut microbiota from 16S rRNA metagenomic data provides a more robust evaluation of gut dysbiosis occurring in Japanese type 2 diabetic patients. J Clin Biochem Nutr. 2017;61:217\u201321. https:\/\/doi.org\/10.3164\/jcbn.17-44.","journal-title":"J Clin Biochem Nutr"},{"key":"4041_CR83","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1172\/JCI86674","volume":"126","author":"S Fujisaka","year":"2016","unstructured":"Fujisaka S, Ussar S, Clish C, Devkota S, Dreyfuss JM, Sakaguchi M, et al. Antibiotic effects on gut microbiota and metabolism are host dependent. J Clin Invest. 2016;126:4430\u201343. https:\/\/doi.org\/10.1172\/JCI86674.","journal-title":"J Clin Invest"},{"key":"4041_CR84","doi-asserted-by":"publisher","first-page":"104513","DOI":"10.1016\/j.isci.2022.104513","volume":"25","author":"C Proffitt","year":"2022","unstructured":"Proffitt C, Bidkhori G, Lee S, Tebani A, Mardinoglu A, Uhlen M, et al. Genome-scale metabolic modelling of the human gut Microbiome reveals changes in the glyoxylate and dicarboxylate metabolism in metabolic disorders. iScience. 2022;25:104513. https:\/\/doi.org\/10.1016\/j.isci.2022.104513.","journal-title":"iScience"},{"key":"4041_CR85","doi-asserted-by":"publisher","first-page":"685204","DOI":"10.1155\/2014\/685204","volume":"2014","author":"VJ Nikiforova","year":"2014","unstructured":"Nikiforova VJ, Giesbertz P, Wiemer J, Bethan B, Looser R, Liebenberg V, et al. Glyoxylate, a new marker metabolite of type 2 diabetes. J Diabetes Res. 2014;2014:685204. https:\/\/doi.org\/10.1155\/2014\/685204.","journal-title":"J Diabetes Res"},{"key":"4041_CR86","doi-asserted-by":"publisher","first-page":"593","DOI":"10.35333\/jrp.2020.207","volume":"24","author":"E Ko\u00e7ak","year":"2020","unstructured":"Ko\u00e7ak E, \u00d6zkul C. Metabolic response of Escherichia coli to subinhibitory concentration of Ofloxacin. J Res Pharm. 2020;24:593\u2013601. https:\/\/doi.org\/10.35333\/jrp.2020.207.","journal-title":"J Res Pharm"},{"key":"4041_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-00073-4","volume":"11","author":"P D\u2019Arpa","year":"2021","unstructured":"D\u2019Arpa P, Karna SLR, Chen T, Leung KP. Pseudomonas aeruginosa transcriptome adaptations from colonization to biofilm infection of skin wounds. Sci Rep. 2021;11:1\u201313. https:\/\/doi.org\/10.1038\/s41598-021-00073-4.","journal-title":"Sci Rep"},{"key":"4041_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2022.1027413","volume":"10 October","author":"Y Dong","year":"2022","unstructured":"Dong Y, Wang P, Yang X, Chen M, Li J. Potential of gut microbiota for lipopolysaccharide biosynthesis in European women with type 2 diabetes based on metagenome. Front Cell Dev Biol. 2022;10 October:1\u201314. https:\/\/doi.org\/10.3389\/fcell.2022.1027413.","journal-title":"Front Cell Dev Biol"},{"key":"4041_CR89","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.2337\/dc18-0253","volume":"41","author":"I Leiva-Gea","year":"2018","unstructured":"Leiva-Gea I, S\u00e1nchez-Alcoholado L, Mart\u00edn-Tejedor B, Castellano-Castillo D, Moreno-Indias I, Urda-Cardona A, et al. Gut microbiota differs in composition and functionality between children with type 1 diabetes and MODY2 and healthy control subjects: A case-control study. Diabetes Care. 2018;41:2385\u201395. https:\/\/doi.org\/10.2337\/dc18-0253.","journal-title":"Diabetes Care"},{"key":"4041_CR90","doi-asserted-by":"publisher","first-page":"65","DOI":"10.12938\/BMFH.2019-031","volume":"40","author":"KS Ibrahim","year":"2020","unstructured":"Ibrahim KS, Bourwis N, Dolan S, Lang S, Spencer J, Craft JA. Characterisation of gut microbiota of obesity and type 2 diabetes in a rodent model. Biosci Microbiota Food Heal. 2020;40:65\u201374. https:\/\/doi.org\/10.12938\/BMFH.2019-031.","journal-title":"Biosci Microbiota Food Heal"},{"key":"4041_CR91","doi-asserted-by":"publisher","unstructured":"Park JU, Oh B, Lee JP, Choi MH, Lee MJ, Kim BS. Influence of microbiota on diabetic foot wound in comparison with adjacent normal skin based on the clinical features. Biomed Res Int. 2019;2019; https:\/\/doi.org\/10.1155\/2019\/7459236","DOI":"10.1155\/2019\/7459236"},{"key":"4041_CR92","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cmet.2009.02.002","volume":"9","author":"CB Newgard","year":"2009","unstructured":"Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A Branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9:311\u201326. https:\/\/doi.org\/10.1016\/j.cmet.2009.02.002.","journal-title":"Cell Metab"},{"key":"4041_CR93","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.numecd.2017.07.001","volume":"27","author":"S Haufe","year":"2017","unstructured":"Haufe S, Engeli S, Kaminski J, Witt H, Rein D, Kamlage B, et al. Branched-chain amino acid catabolism rather than amino acids plasma concentrations is associated with diet-induced changes in insulin resistance in overweight to obese individuals. Nutr Metab Cardiovasc Dis. 2017;27:858\u201364. https:\/\/doi.org\/10.1016\/j.numecd.2017.07.001.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"4041_CR94","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jgar.2023.05.008","volume":"34","author":"X Zhang","year":"2023","unstructured":"Zhang X, Li H, Wang Y, Kang Y, Li Z. Metagenomic analysis reveals antibiotic resistance profiles in tissue samples from patients with diabetic foot infections. J Glob Antimicrob Resist. 2023;34:202\u201310. https:\/\/doi.org\/10.1016\/j.jgar.2023.05.008.","journal-title":"J Glob Antimicrob Resist"},{"key":"4041_CR95","doi-asserted-by":"publisher","unstructured":"Prevel R, Enaud R, Orieux A, Camino A, Sioniac P, M\u2019Zali F, et al. Bridging gut microbiota composition with extended-spectrum beta-lactamase Enterobacteriales faecal carriage in critically ill patients (microbe cohort study). Ann Intensive Care. 2023;13. https:\/\/doi.org\/10.1186\/s13613-023-01121-0.","DOI":"10.1186\/s13613-023-01121-0"},{"key":"4041_CR96","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10096-019-03798-3","volume":"39","author":"M Aires-de-Sousa","year":"2020","unstructured":"Aires-de-Sousa M, Lopes E, Gon\u00e7alves ML, Pereira AL, Machado e Costa A, de Lencastre H, et al. Intestinal carriage of extended-spectrum beta-lactamase\u2013producing Enterobacteriaceae at admission in a Portuguese hospital. Eur J Clin Microbiol Infect Dis. 2020;39:783\u201390. https:\/\/doi.org\/10.1007\/s10096-019-03798-3.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4041_CR97","doi-asserted-by":"publisher","unstructured":"Brolund A. Overview of ESBL-producing Enterobacteriaceae from a nordic perspective. Infect Ecol Epidemiol. 2014;4. https:\/\/doi.org\/10.3402\/iee.v4.24555.","DOI":"10.3402\/iee.v4.24555"},{"key":"4041_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-014-0189-7","volume":"14","author":"SC Bischoff","year":"2014","unstructured":"Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability - a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:1\u201325. https:\/\/doi.org\/10.1186\/s12876-014-0189-7.","journal-title":"BMC Gastroenterol"},{"key":"4041_CR99","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/gutjnl-2019-318427","volume":"68","author":"M Camilleri","year":"2019","unstructured":"Camilleri M. Leaky Gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68:1516\u201326. https:\/\/doi.org\/10.1136\/gutjnl-2019-318427.","journal-title":"Gut"},{"key":"4041_CR100","doi-asserted-by":"publisher","first-page":"65052","DOI":"10.1007\/s11356-021-16781-3","volume":"28","author":"J Zhou","year":"2021","unstructured":"Zhou J, Lin Y, Liu Y, Chen K. Antibiotic exposure and risk of type 2 diabetes mellitus: a systematic review and meta-analysis. Environ Sci Pollut Res. 2021;28:65052\u201361. https:\/\/doi.org\/10.1007\/s11356-021-16781-3.","journal-title":"Environ Sci Pollut Res"},{"key":"4041_CR101","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1530\/EJE-14-1163","volume":"172","author":"B Boursi","year":"2015","unstructured":"Boursi B, Mamtani R, Haynes K, Yang YX. The effect of past antibiotic exposure on diabetes risk. Eur J Endocrinol. 2015;172:639\u201348. https:\/\/doi.org\/10.1530\/EJE-14-1163.","journal-title":"Eur J Endocrinol"},{"key":"4041_CR102","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2337\/dc19-1162","volume":"43","author":"ML Wernroth","year":"2020","unstructured":"Wernroth ML, Fall K, Svennblad B, Ludvigsson JF, Sj\u00f6lander A, Almqvist C, et al. Early childhood antibiotic treatment for otitis media and other respiratory tract infections is associated with risk of type 1 diabetes: A nationwide register-based study with sibling analysis. Diabetes Care. 2020;43:991\u20139. https:\/\/doi.org\/10.2337\/dc19-1162.","journal-title":"Diabetes Care"},{"key":"4041_CR103","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/pedi.13111","volume":"21","author":"JC Antvorskov","year":"2020","unstructured":"Antvorskov JC, Morgen CS, Buschard K, Jess T, Allin KH, Josefsen K. Antibiotic treatment during early childhood and risk of type 1 diabetes in children: A National birth cohort study. Pediatr Diabetes. 2020;21:1457\u201364. https:\/\/doi.org\/10.1111\/pedi.13111.","journal-title":"Pediatr Diabetes"},{"key":"4041_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0144854","volume":"10","author":"MVL Tulstrup","year":"2015","unstructured":"Tulstrup MVL, Christensen EG, Carvalho V, Linninge C, Ahrn\u00e9 S, H\u00f8jberg O, et al. Antibiotic treatment affects intestinal permeability and gut microbial composition in Wistar rats dependent on antibiotic class. PLoS ONE. 2015;10:1\u201317. https:\/\/doi.org\/10.1371\/journal.pone.0144854.","journal-title":"PLoS ONE"},{"key":"4041_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics13050413","volume":"13","author":"W Abbas","year":"2024","unstructured":"Abbas W, Bi R, Hussain MD, Tajdar A, Guo F, Guo Y, et al. Antibiotic cocktail effects on intestinal microbial community, barrier function, and immune function in early broiler chickens. Antibiotics. 2024;13:1\u201321. https:\/\/doi.org\/10.3390\/Antibiotics13050413.","journal-title":"Antibiotics"},{"key":"4041_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21176108","volume":"21","author":"Y Ran","year":"2020","unstructured":"Ran Y, Fukui H, Xu X, Wang X, Ebisutani N, Tanaka Y, et al. Alteration of colonic mucosal permeability during antibiotic-induced dysbiosis. Int J Mol Sci. 2020;21:1\u201314. https:\/\/doi.org\/10.3390\/ijms21176108.","journal-title":"Int J Mol Sci"},{"key":"4041_CR107","doi-asserted-by":"publisher","first-page":"101507","DOI":"10.1016\/j.beem.2021.101507","volume":"35","author":"M Snelson","year":"2021","unstructured":"Snelson M, de Pasquale C, Ekinci EI, Coughlan MT. Gut microbiome, prebiotics, intestinal permeability and diabetes complications. Best Pract Res Clin Endocrinol Metab. 2021;35:101507. https:\/\/doi.org\/10.1016\/j.beem.2021.101507.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4041_CR108","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.aimed.2018.08.003","volume":"6","author":"B Leech","year":"2019","unstructured":"Leech B, Schloss J, Steel A. Association between increased intestinal permeability and disease: A systematic review. Adv Integr Med. 2019;6:23\u201334. https:\/\/doi.org\/10.1016\/j.aimed.2018.08.003.","journal-title":"Adv Integr Med"},{"key":"4041_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1926841","volume":"13","author":"P Mokhtari","year":"2021","unstructured":"Mokhtari P, Metos J, Anandh Babu PV. Impact of type 1 diabetes on the composition and functional potential of gut Microbiome in children and adolescents: possible mechanisms, current knowledge, and challenges. Gut Microbes. 2021;13:1\u201318. https:\/\/doi.org\/10.1080\/19490976.2021.1926841.","journal-title":"Gut Microbes"},{"key":"4041_CR110","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.diabet.2016.09.004","volume":"43","author":"AJ Cox","year":"2017","unstructured":"Cox AJ, Zhang P, Bowden DW, Devereaux B, Davoren PM, Cripps AW, et al. Increased intestinal permeability as a risk factor for type 2 diabetes. Diabetes Metab. 2017;43:163\u20136. https:\/\/doi.org\/10.1016\/j.diabet.2016.09.004.","journal-title":"Diabetes Metab"},{"key":"4041_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.00125","volume":"11 March","author":"H Zhou","year":"2020","unstructured":"Zhou H, Sun L, Zhang S, Zhao X, Gang X, Wang G. Evaluating the causal role of gut microbiota in type 1 diabetes and its possible pathogenic mechanisms. Front Endocrinol (Lausanne). 2020;11 March:1\u201313. https:\/\/doi.org\/10.3389\/fendo.2020.00125.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4041_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-56662-x","volume":"9","author":"G Nah","year":"2019","unstructured":"Nah G, Park SC, Kim K, Kim S, Park J, Lee S, et al. Type-2 diabetics reduces Spatial variation of Microbiome based on extracellur vesicles from gut microbes across human body. Sci Rep. 2019;9:1\u201310. https:\/\/doi.org\/10.1038\/s41598-019-56662-x.","journal-title":"Sci Rep"},{"key":"4041_CR113","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/pedi.12865","volume":"20","author":"JE Harbison","year":"2019","unstructured":"Harbison JE, Roth-Schulze AJ, Giles LC, Tran CD, Ngui KM, Penno MA, et al. Gut Microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes: A prospective cohort study. Pediatr Diabetes. 2019;20:574\u201383. https:\/\/doi.org\/10.1111\/pedi.12865.","journal-title":"Pediatr Diabetes"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04041-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-04041-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-04041-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T05:02:48Z","timestamp":1748408568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-025-04041-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4041"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-04041-0","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans were approved by the ethics committees of the Institute for Clinical and Experimental Medicine and Thomayer University Hospital (Prague, Czech Republic). The DFIATIM Clinical Trial (Full title: \u201cRationalisation of ATB therapy in diabetic foot infection and its impact on the intestinal microbiota\u201d) is submitted to the European Union Clinical Trials Database under the EudraCT Number: 2019-001997-27. This study was conducted following the local legislation and institutional requirements and in accordance with the ethical principles outlined in the Declaration of Helsinki. All participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"339"}}